Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)

BACKGROUND: Respiratory syncytial virus infection causes respiratory diseases in about 90% of the children under 2 years of age. Currently the only way to prevent infection is through immunoprophylaxis based on palivizumab. AIM: The aim of the study was to assess compliance with the recommended prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Borecka, Róża, Lauterbach, Ryszard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2019
Materias:
Original Article/Praca Oryginalna
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522825/
https://www.ncbi.nlm.nih.gov/pubmed/30636227
http://dx.doi.org/10.34763/devperiodmed.20182204.308314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522825/
https://www.ncbi.nlm.nih.gov/pubmed/30636227
http://dx.doi.org/10.34763/devperiodmed.20182204.308314

Ejemplares similares